An Open-label Study of Tiagabine as Augmentation Therapy for Anxiety

References

• Kessler RC, McGonagle KA, Zhao S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3:171–199
   PubMedGoogle Scholar
• Ballenger JC: Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry 2001; 62\(suppl 19):11–19
   Google Scholar
• Pollack MH, Zaninelli R, Goddard A et al.: Paroxetine in the treatment of generalized anxiety disorder: Results of a placebocontrolled, flexible-dosage trial. J Clin Psychiatry 2001; 62:350–357
   PubMed Web of Science ®Google Scholar
• Ninan PT: The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999; 60\(suppl 22):12–17
   Google Scholar
• Nutt DJ, Malizia AL: New insights into the role of the GABAAbenzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001; 179:390–396
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuikka J, Rasanen P et al.: Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 1997; 2:463–471
   PubMed Web of Science ®Google Scholar
• Malizia AL, Cunningham VJ, Bell CJ et al.: Decreased brain GABAA-benzodiazepine receptor binding in panic disorder: Preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55:715–720
   PubMed Web of Science ®Google Scholar
• Bremner JD, Innis RB, White T et al.: SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000; 47:96–106
   PubMed Web of Science ®Google Scholar
• Goddard AW, Mason GF, Almai A et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58:556–561
   PubMed Web of Science ®Google Scholar
• Fink-Jensen A, Suzdak PD, Swedberg MD et al.: The gammaaminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220:197–201
   PubMed Web of Science ®Google Scholar
• Borden LA, Murali Dhar TG, Smith KE et al.: Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269:219–224
   PubMedGoogle Scholar
• Suzdak PD, Jansen JA: A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36(6):612–626
   PubMed Web of Science ®Google Scholar
• Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64:1245–1249
   PubMed Web of Science ®Google Scholar
• Adkins JC, Noble S: Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55:437–460
   Google Scholar
• American Psychiatric Association: Anxiety disorders. In: Diagnostic and Statistical Manual of Mental Disorders,, Text Revision. 4th. Washington, DC: American Psychiatric Association, 2000:429–484
   Google Scholar
• Guy W.: Clinical global impression of change (CGI-C) (rating scale). In: ECDEU Assessment Manual for Psychopharmacology. Washington, D.C.: National Institute of Mental Health, US Department of Health, Education, and Welfare, 1976
   Google Scholar
• Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50–55
   PubMed Web of Science ®Google Scholar
• Beck AT, Epstein N, Brown G et al.: An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56:893–897
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, 3rd, Monk TH et al: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193–213
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–483
   Google Scholar
• Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptictreated patients. Acta Psychiatr Scand Suppl 1987; 76:1–100
   Google Scholar
• Ballenger JC: Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60\(suppl 22):29–34
   Google Scholar
• Leppik IE, Gram L, Deaton R et al.: Safety of tiagabine: Summary of 53 trials. Epilepsy Res 1999; 33:235–246
   PubMed Web of Science ®Google Scholar
• Berigan T: Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry 2002; 47:788
   Google Scholar
• Schwartz TL: The use of tiagabine augmentation for treatmentresistant anxiety disorders: a case series. Psychopharmacol Bull 2002; 36:53–57
   PubMedGoogle Scholar
• Crane D: Tiagabine for the treatment of anxiety. Depress Anxiety 2003; 18:51–52
   PubMed Web of Science ®Google Scholar
• Van Ameringen M, Pollack MH, et al. Poster presented at CINP, 2004
   Google Scholar